Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Menter

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
The British Journal of Dermatology|May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasisC Ryan, A Menter, L Guenther, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
The Journal of Clinical Investigation|May 4, 1999
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgarisJ R Abrams, M G Lebwohl, C A Guzzo, et al.
The British Journal of Dermatology|July 22, 2004
Biological therapies in the systemic management of psoriasis: International Consensus ConferenceW Sterry, J Barker, W-H Boehncke, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2009
European S3-guidelines on the systemic treatment of psoriasis vulgarisD Pathirana, A D Ormerod, P Saiag, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
The British Journal of Dermatology|May 11, 2018
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasisC Ryan, A Menter, L Guenther, et al.
Journal of the American Academy of Dermatology|July 25, 2000
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?G G Krueger, S R Feldman, C Camisa, et al.
The Journal of Clinical Investigation|May 4, 1999
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgarisJ R Abrams, M G Lebwohl, C A Guzzo, et al.
The British Journal of Dermatology|July 22, 2004
Biological therapies in the systemic management of psoriasis: International Consensus ConferenceW Sterry, J Barker, W-H Boehncke, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 29, 2009
European S3-guidelines on the systemic treatment of psoriasis vulgarisD Pathirana, A D Ormerod, P Saiag, et al.
Pageof 12